AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Effects: Punicic acid exhibits anti-inflammatory properties, which may help reduce inflammation and alleviate symptoms associated with inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease (IBD), and asthma. Punicic acid can inhibit the production of pro-inflammatory cytokines and mediators, thereby attenuating inflammatory responses and tissue damage.
Cardiovascular Health: Punicic acid has been shown to have beneficial effects on cardiovascular health by reducing risk factors associated with heart disease. It can lower levels of LDL (low-density lipoprotein) cholesterol, commonly referred to as "bad" cholesterol, and increase levels of HDL (high-density lipoprotein) cholesterol, known as "good" cholesterol. Punicic acid may also help improve lipid profiles, reduce triglyceride levels, and prevent the development of atherosclerosis and cardiovascular events.
Antioxidant Activity: Punicic acid possesses antioxidant properties, which help protect cells and tissues from oxidative stress and damage caused by free radicals. Antioxidants play a crucial role in maintaining overall health and reducing the risk of chronic diseases such as cancer, diabetes, and neurodegenerative disorders. Punicic acid's antioxidant activity may contribute to its potential health benefits and protective effects against oxidative damage.
Skin Health: Pomegranate seed oil, rich in punicic acid, is often used in skincare products due to its moisturizing, anti-inflammatory, and antioxidant properties. Punicic acid may help promote skin health by enhancing skin barrier function, reducing inflammation, and protecting against UV-induced damage. It may also stimulate collagen production and improve skin elasticity, leading to a more youthful and radiant complexion.
Anti-cancer Effects: Some research suggests that punicic acid may have anti-cancer properties and inhibit the growth and proliferation of cancer cells. Punicic acid can induce apoptosis (programmed cell death) in cancer cells, suppress tumor cell invasion and metastasis, and modulate signaling pathways involved in cancer development and progression. Pomegranate seed oil and punicic acid derivatives have been investigated for their potential as adjunctive treatments for various types of cancer, including breast, prostate, and colon cancer.
Metabolic Health: Punicic acid may have beneficial effects on metabolic health and glucose metabolism. It can improve insulin sensitivity, reduce insulin resistance, and lower blood glucose levels, which may help prevent or manage type 2 diabetes and metabolic syndrome. Punicic acid's ability to modulate lipid metabolism and adipocyte function may also contribute to its metabolic benefits.
Rank | Probiotic | Impact |
---|---|---|
species | Lactobacillus acidophilus | Increases |
species | Lactobacillus crispatus | Increases |
species | Lactobacillus gasseri | Increases |
species | Lactobacillus helveticus | Increases |
species | Lactobacillus jensenii | Increases |
species | Lactobacillus johnsonii | Increases |
species | Lactobacillus kefiranofaciens | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
π Direct Citations | πͺπΆ Indirect Citations | Taxonomy | Rank | Effect |
---|---|---|---|---|
1 | 0 | Desulfovibrionaceae | family | Decreases |
1 | 0 | Helicobacteraceae | family | Decreases |
0 | 1 | Erysipelotrichaceae | family | Decreases |
0 | 1 | Lactobacillaceae | family | Increases |
0 | 1 | Oscillospiraceae | family | Increases |
0 | 1 | Lachnospiraceae | family | Increases |
2 | 0 | Muribaculaceae | family | Increases |
0 | 1 | Helicobacter | genus | Decreases |
0 | 1 | Bilophila | genus | Decreases |
1 | 0 | Anaerotruncus | genus | Decreases |
1 | 0 | Blautia | genus | Decreases |
1 | 0 | Faecalibaculum | genus | Decreases |
0 | 1 | Desulfobaculum | genus | Decreases |
0 | 1 | Desulfocurvibacter | genus | Decreases |
0 | 1 | Desulfocurvus | genus | Decreases |
0 | 1 | Desulfohalovibrio | genus | Decreases |
0 | 1 | Flexispira | genus | Decreases |
0 | 1 | Fundidesulfovibrio | genus | Decreases |
0 | 1 | Halodesulfovibrio | genus | Decreases |
0 | 1 | Humidesulfovibrio | genus | Decreases |
0 | 1 | Mailhella | genus | Decreases |
0 | 1 | Nitratidesulfovibrio | genus | Decreases |
0 | 1 | Paradesulfovibrio (ex Waite et al. 2020) | genus | Decreases |
0 | 1 | Paucidesulfovibrio | genus | Decreases |
0 | 1 | Salidesulfovibrio | genus | Decreases |
0 | 1 | Wolinella | genus | Decreases |
0 | 1 | Maridesulfovibrio | genus | Decreases |
0 | 1 | Desulfovibrio | genus | Decreases |
0 | 1 | Megalodesulfovibrio | genus | Decreases |
0 | 1 | Desulfolutivibrio | genus | Decreases |
0 | 1 | Solidesulfovibrio | genus | Decreases |
0 | 1 | Oleidesulfovibrio | genus | Decreases |
0 | 1 | Oceanidesulfovibrio | genus | Decreases |
0 | 1 | Lawsonia | genus | Decreases |
0 | 1 | Pseudodesulfovibrio | genus | Decreases |
0 | 1 | Muribaculum | genus | Increases |
0 | 1 | Sodaliphilus | genus | Increases |
0 | 1 | Candidatus Amulumruptor | genus | Increases |
0 | 1 | Candidatus Homeothermus | genus | Increases |
0 | 1 | Paramuribaculum | genus | Increases |
0 | 1 | Duncaniella | genus | Increases |
1 | 0 | Lactobacillus | genus | Increases |
1 | 0 | Oscillibacter | genus | Increases |
1 | 0 | Roseburia | genus | Increases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | environmental samples | no rank | Decreases |
0 | 1 | unclassified Anaerotruncus | no rank | Decreases |
0 | 1 | unclassified Desulfovibrionaceae | no rank | Decreases |
0 | 1 | environmental samples | no rank | Increases |
0 | 1 | environmental samples | no rank | Increases |
0 | 1 | environmental samples | no rank | Increases |
0 | 1 | environmental samples | no rank | Increases |
0 | 1 | unclassified Lactobacillus | no rank | Increases |
0 | 1 | unclassified Muribaculaceae | no rank | Increases |
0 | 1 | unclassified Oscillibacter | no rank | Increases |
0 | 1 | unclassified Roseburia | no rank | Increases |
0 | 1 | Desulfovibrionales | order | Decreases |
0 | 1 | Campylobacterales | order | Decreases |
0 | 1 | Bacteroidales | order | Increases |
0 | 1 | Anaerotruncus colihominis | species | Decreases |
0 | 1 | Faecalibaculum rodentium | species | Decreases |
0 | 1 | Anaerotruncus massiliensis (ex Liu et al. 2021) | species | Decreases |
0 | 1 | Anaerotruncus massiliensis (ex Togo et al. 2019) | species | Decreases |
0 | 1 | Anaerotruncus rubiinfantis | species | Decreases |
0 | 1 | Lactobacillus ultunensis | species | Increases |
0 | 1 | Lactobacillus helveticus | species | Increases |
0 | 1 | Lactobacillus johnsonii | species | Increases |
0 | 1 | Lactobacillus kefiranofaciens | species | Increases |
0 | 1 | Lactobacillus amylolyticus | species | Increases |
0 | 1 | Lactobacillus acetotolerans | species | Increases |
0 | 1 | Lactobacillus amylovorus | species | Increases |
0 | 1 | Lactobacillus iners | species | Increases |
0 | 1 | Lactobacillus taiwanensis | species | Increases |
0 | 1 | Lactobacillus crispatus | species | Increases |
0 | 1 | Lactobacillus intestinalis | species | Increases |
0 | 1 | Lactobacillus acidophilus | species | Increases |
0 | 1 | Lactobacillus paragasseri | species | Increases |
0 | 1 | Lactobacillus jensenii | species | Increases |
0 | 1 | Lactobacillus gasseri | species | Increases |
0 | 1 | [Lactobacillus] rogosae | species | Increases |
0 | 1 | ATCC 15434 | species | Increases |
0 | 1 | Candidatus Oscillibacter avistercoris | species | Increases |
0 | 1 | Candidatus Oscillibacter excrementavium | species | Increases |
0 | 1 | Candidatus Oscillibacter pullicola | species | Increases |
0 | 1 | Lactobacillus alvei | species | Increases |
0 | 1 | Lactobacillus animata | species | Increases |
0 | 1 | Lactobacillus apis | species | Increases |
0 | 1 | Lactobacillus bombicola | species | Increases |
0 | 1 | Lactobacillus brevisimilis | species | Increases |
0 | 1 | Lactobacillus equicursoris | species | Increases |
0 | 1 | Lactobacillus faeni | species | Increases |
0 | 1 | Lactobacillus fornicalis | species | Increases |
0 | 1 | Lactobacillus gallinarum | species | Increases |
0 | 1 | Lactobacillus gigeriorum | species | Increases |
0 | 1 | Lactobacillus guizhouensis | species | Increases |
0 | 1 | Lactobacillus hamsteri | species | Increases |
0 | 1 | Lactobacillus helsingborgensis | species | Increases |
0 | 1 | Lactobacillus hominis | species | Increases |
0 | 1 | Lactobacillus intermedius | species | Increases |
0 | 1 | Lactobacillus japonicus | species | Increases |
0 | 1 | Lactobacillus kalixensis | species | Increases |
0 | 1 | Lactobacillus kitasatonis | species | Increases |
0 | 1 | Lactobacillus kullabergensis | species | Increases |
0 | 1 | Lactobacillus leichmannii | species | Increases |
0 | 1 | Lactobacillus letivazi | species | Increases |
0 | 1 | Lactobacillus mulieris | species | Increases |
0 | 1 | Lactobacillus panisapium | species | Increases |
0 | 1 | Lactobacillus pasteurii | species | Increases |
0 | 1 | Lactobacillus psittaci | species | Increases |
0 | 1 | Lactobacillus rodentium | species | Increases |
0 | 1 | Lactobacillus selangorensis | species | Increases |
0 | 1 | Lactobacillus sp. 7_1_47FAA | species | Increases |
0 | 1 | Lactobacillus sp. MYMRS/TEN2 | species | Increases |
0 | 1 | Lactobacillus terrae | species | Increases |
0 | 1 | Oscillibacter acetigenes | species | Increases |
0 | 1 | Oscillibacter massiliensis | species | Increases |
0 | 1 | Oscillibacter ruminantium | species | Increases |
0 | 1 | Oscillibacter valericigenes | species | Increases |
0 | 1 | Roseburia cecicola | species | Increases |
0 | 1 | Roseburia difficilis | species | Increases |
0 | 1 | Roseburia faecis | species | Increases |
0 | 1 | Roseburia inulinivorans | species | Increases |
0 | 1 | Roseburia lenta | species | Increases |
0 | 1 | Roseburia porci | species | Increases |
0 | 1 | Roseburia yibonii | species | Increases |
0 | 1 | Roseburia zhanii | species | Increases |
0 | 1 | Lactobacillus delbrueckii | species | Increases |
0 | 1 | Roseburia hominis | species | Increases |
0 | 1 | Roseburia rectibacter | species | Increases |
0 | 1 | Roseburia intestinalis | species | Increases |
0 | 1 | Oscillibacter hominis | species | Increases |
0 | 1 | Lactobacillus casei group | species group | Increases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.6 | 0.5 | 0.2 |
Acne | 1 | 1 | |
ADHD | 1.1 | 1.5 | -0.36 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.6 | -0.2 |
Allergic Rhinitis (Hay Fever) | 2.4 | 0.3 | 7 |
Allergies | 3 | 2.2 | 0.36 |
Allergy to milk products | 0.3 | 0.8 | -1.67 |
Alopecia (Hair Loss) | 0.5 | 0.3 | 0.67 |
Alzheimer's disease | 5.7 | 2.4 | 1.38 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.8 | 1.7 | -1.13 |
Ankylosing spondylitis | 1.7 | 1.5 | 0.13 |
Anorexia Nervosa | 1.7 | 0.8 | 1.13 |
Antiphospholipid syndrome (APS) | 1.1 | -1.1 | |
Asthma | 3 | 1.5 | 1 |
Atherosclerosis | 1.7 | 0.6 | 1.83 |
Atrial fibrillation | 1.6 | 1.2 | 0.33 |
Autism | 2.5 | 4 | -0.6 |
Autoimmune Disease | 2.1 | 2.1 | |
Barrett esophagus cancer | 0 | 0 | |
benign prostatic hyperplasia | 0.2 | 0.2 | |
Bipolar Disorder | 1.4 | 0.6 | 1.33 |
Brain Trauma | 1.7 | 0.9 | 0.89 |
Breast Cancer | 0.3 | -0.3 | |
Cancer (General) | 0.7 | 0.7 | |
Carcinoma | 1.1 | 1.6 | -0.45 |
Celiac Disease | 2 | 3 | -0.5 |
Cerebral Palsy | 0.6 | 1.1 | -0.83 |
Chronic Fatigue Syndrome | 2.2 | 0.9 | 1.44 |
Chronic Kidney Disease | 2 | 1.2 | 0.67 |
Chronic Lyme | 0.6 | 0.6 | |
Chronic Obstructive Pulmonary Disease (COPD) | 0.8 | 2 | -1.5 |
Coagulation / Micro clot triggering bacteria | 0.6 | 0.5 | 0.2 |
Cognitive Function | 1.4 | 1.3 | 0.08 |
Colorectal Cancer | 3 | 3 | 0 |
Constipation | 0.6 | 1 | -0.67 |
Coronary artery disease | 1.7 | 0.8 | 1.13 |
COVID-19 | 4.1 | 1.4 | 1.93 |
Crohn's Disease | 3.8 | 3.5 | 0.09 |
Cushing's Syndrome (hypercortisolism) | 0 | 0 | |
cystic fibrosis | 0.8 | 0.5 | 0.6 |
d-lactic acidosis (one form of brain fog) | 1 | -1 | |
deep vein thrombosis | 1.6 | 0.6 | 1.67 |
Denture Wearers Oral Shifts | 0.6 | 0.6 | |
Depression | 5.6 | 3.9 | 0.44 |
Dermatomyositis | 0.5 | -0.5 | |
Eczema | 0.2 | 0.3 | -0.5 |
Endometriosis | 2.8 | 0.6 | 3.67 |
Epilepsy | 1.4 | 0.8 | 0.75 |
erectile dysfunction | 0.3 | 0.9 | -2 |
Fibromyalgia | 1.4 | 1.2 | 0.17 |
Functional constipation / chronic idiopathic constipation | 1.4 | 1.7 | -0.21 |
gallstone disease (gsd) | 2.8 | 0.2 | 13 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.6 | -0.2 |
Generalized anxiety disorder | 1.4 | 0.4 | 2.5 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | 0.5 | |
Gout | 0.5 | 0.9 | -0.8 |
Graves' disease | 1.5 | 1.4 | 0.07 |
Gulf War Syndrome | 0.8 | 0.8 | |
Hashimoto's thyroiditis | 1.3 | 2.5 | -0.92 |
Heart Failure | 2.1 | 1.1 | 0.91 |
hemorrhagic stroke | 0.3 | -0.3 | |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
High Histamine/low DAO | 1.2 | -1.2 | |
hypercholesterolemia (High Cholesterol) | 0 | 0 | |
hyperglycemia | 1.2 | 1 | 0.2 |
Hyperlipidemia (High Blood Fats) | 3.4 | 0.6 | 4.67 |
hypersomnia | 0.3 | 1.1 | -2.67 |
hypertension (High Blood Pressure | 4.2 | 2.3 | 0.83 |
Hypothyroidism | 0.5 | 0.7 | -0.4 |
Hypoxia | 0.6 | 1.2 | -1 |
IgA nephropathy (IgAN) | 1.5 | 0.3 | 4 |
Inflammatory Bowel Disease | 3.5 | 1.5 | 1.33 |
Insomnia | 1.5 | 2.7 | -0.8 |
Intelligence | 0.6 | 0.5 | 0.2 |
Intracranial aneurysms | 1.6 | 0.2 | 7 |
Irritable Bowel Syndrome | 2.7 | 2.3 | 0.17 |
ischemic stroke | 2 | 0.6 | 2.33 |
Liver Cirrhosis | 3.2 | 3 | 0.07 |
Long COVID | 4.3 | 2.8 | 0.54 |
Low bone mineral density | 1.1 | 1.1 | |
Lung Cancer | 1.6 | 0.5 | 2.2 |
Lymphoma | 0 | 0 | |
Mast Cell Issues / mastitis | 0.6 | 0.6 | |
ME/CFS with IBS | 0.3 | 0.3 | |
ME/CFS without IBS | |||
Menopause | 1.3 | 1.3 | |
Metabolic Syndrome | 5 | 3.3 | 0.52 |
Mood Disorders | 5.2 | 3.6 | 0.44 |
multiple chemical sensitivity [MCS] | 1.1 | -1.1 | |
Multiple Sclerosis | 4.4 | 1.4 | 2.14 |
Multiple system atrophy (MSA) | 1.5 | -1.5 | |
myasthenia gravis | 0.6 | 0.3 | 1 |
neuropathic pain | 1.3 | 0.5 | 1.6 |
Neuropathy (all types) | 2 | 0.9 | 1.22 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0 | 0 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.5 | 2.7 | 0.67 |
NonCeliac Gluten Sensitivity | 1.1 | 0.2 | 4.5 |
Obesity | 6.4 | 5 | 0.28 |
obsessive-compulsive disorder | 0.9 | 0.5 | 0.8 |
Osteoarthritis | 0.8 | 0.3 | 1.67 |
Osteoporosis | 1.2 | 2.5 | -1.08 |
pancreatic cancer | 0.3 | 0.2 | 0.5 |
Parkinson's Disease | 4.3 | 3.3 | 0.3 |
Peanut Allergy | 0.3 | 0.6 | -1 |
Polycystic ovary syndrome | 3 | 3.1 | -0.03 |
Premenstrual dysphoric disorder | 0.5 | 0.5 | |
primary biliary cholangitis | 0.2 | 1.5 | -6.5 |
Primary sclerosing cholangitis | 0.3 | 1.3 | -3.33 |
Psoriasis | 1.7 | 0.6 | 1.83 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.4 | 3.6 | 0.5 |
Rosacea | 1.8 | 0.3 | 5 |
Schizophrenia | 3.9 | 2.3 | 0.7 |
scoliosis | 1.1 | -1.1 | |
sensorineural hearing loss | 0.3 | 0.3 | |
Sjögren syndrome | 0.8 | 0.7 | 0.14 |
Sleep Apnea | 1.1 | 1.3 | -0.18 |
Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | 0.8 | -3 |
Stress / posttraumatic stress disorder | 0.9 | 1.2 | -0.33 |
Systemic Lupus Erythematosus | 2.8 | 1.3 | 1.15 |
Tic Disorder | 0.3 | 0.2 | 0.5 |
Tourette syndrome | 0.8 | 0.8 | |
Type 1 Diabetes | 2.5 | 0.9 | 1.78 |
Type 2 Diabetes | 3.6 | 2.4 | 0.5 |
Ulcerative colitis | 3.6 | 3 | 0.2 |
Unhealthy Ageing | 2 | 0.6 | 2.33 |
Vitiligo | 0.3 | 0.3 | 0 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]